Pfizer
Arthur Bergman is a highly experienced clinical pharmacology professional with over two decades in the pharmaceutical industry. At Pfizer, Arthur served as Executive Director and Clinical Pharmacology Group Head for Anti-Infectives from February 2012 to June 2024, and previously held roles including Senior Director and Director focused on Clinical Pharmacology support for Internal Medicine programs. Prior to Pfizer, Arthur worked at Merck as a PK/PD Scientist from May 2000 to July 2010. Academic credentials include a PhD in Chemical Engineering from Rice University and a BS in Chemical Engineering from Penn State University.
This person is not in any teams
This person is not in any offices
Pfizer
614 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.